Fundraising Fox마이크로바이오틱스
Seoul, KR · 2 known investors
Find your way into 마이크로바이오틱스
Sign up to see every warm intro you have to 마이크로바이오틱스
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 마이크로바이오틱스 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.
Investors · 2
Frequently asked questions
- What does 마이크로바이오틱스 do?
- MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.
- Who are 마이크로바이오틱스's investors?
- 마이크로바이오틱스's investors include Schmidt, Solidus Investment.
- Where is 마이크로바이오틱스 headquartered?
- 마이크로바이오틱스 is headquartered in Seoul, KR.